Eyenovia, Inc. EYEN announced the decision to terminate a phase III study evaluating its investigational drug-device product, MicroPine, as a potential treatment for pediatric progressive myopia.
TipRanks on MSN
AbbVie’s AML Study Termination: Implications for Investors
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie has recently provided an update on its Phase 3 ...
The SEC’s temporary de minimis thresholds for security-based swap dealing activity ($8 billion for credit default swaps and ...
Co announces that the independent Data Safety Monitoring Board for the pivotal Phase III trial of tesmilifene in patients with metastatic or recurrent breast cancer has completed its third planned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback